
Join to view full profile
20 York StYnhh - West Pavilion, 2nd FloorNew Haven, CT 06510
Phone+1 203-785-4081
Fax+1 203-785-3833
Dr. Masiukiewicz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1996 - 1998
UMass Chan Medical SchoolResidency, Internal Medicine, 1993 - 1996
Medical University of WarsawClass of 1985
Certifications & Licensure
CT State Medical License 1997 - 2027
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 1 citationsHeart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTI...Ambarish Pandey, Ahmed A Kolkailah, Darren K McGuire, Robert C Frederich, Nilo B Cater
European Journal of Heart Failure. 2025-03-01 - 2 citationsCardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Recep...David Z I Cherney, Robert Frederich, Richard E Pratley, Francesco Cosentino, Samuel Dagogo-Jack
Kidney Diseases. 2025-02-04 - 3 citationsErtugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi
The Journal of Clinical Endocrinology and Metabolism. 2023-07-14
Journal Articles
- Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 DiabetesDarren K Mcguire, Urszula Masiukiewicz, JAMA Cardiology
- Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesSamuel Dagogo-Jack, Urszula Masiukiewicz, Robert Frederich, Darren K Mcguire, The New England Journal of Medicine
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: